免疫および成長因子シグナル伝達経路は,乳がん患者の抗タイプI型インスリン型の成長因子受容体療法に対する病理学的完全反応と関連している
Emmanuel F Petricoin1, Denise M Wolf2, Christina Yau3
1Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia.
まとめ
乳がんにおけるバイオマーカーの分析では,インスリン類似成長因子1受容体 (IGF- 1R) と免疫マーカーの活性化が,特にホルモン受容体陽性腫瘍において,ネオアジュバント療法に対する治療反応を予測することが示された.
科学分野:
- 腫瘍学
- 分子生物学
- 免疫学
背景:
- ネオアジュバント乳がん治療は,手術前に腫瘍のサイズを減らすことを目的としています.
- 予測可能なバイオマーカーを特定することは,個別化された治療法の選択に不可欠です.
- I-SPY2試験では,IGF-1Rを標的とする薬剤を含む新規補助剤の投与法を調査した.
研究 の 目的:
- パクリタキセル,ガンチタブ (抗IGF- 1R抗体),メトホルミン (PGM) による病理学的完全反応 (pCR) を予測するバイオマーカーを特定する.
- PGMアームと対照化学療法アームのバイオマーカー関連を比較する.
- 治療反応におけるIGF-1R経路の活性化と免疫マーカーの役割を調査する.
主な方法:
- I-SPY2試験参加者の治療前の腫瘍サンプルを分析した.
- レーザー捕捉マイクロ解剖と 逆相タンパク質配列を用いた
- IGF-1R経路における32の既定バイオマーカーと109の探索用マーカーを評価した.
主要な成果:
- リン酸化IGF-1R/インスリン受容体 (IR) 濃度の上昇は,特にホルモン受容体 (HR) 陽性乳がんにおいて,PCRの増加と相関する.
- HR+およびHR- 腫瘍の異なるパターンを持つpCRに関連した免疫応答マーカー.
- PGMで治療されたHR腫瘍におけるpCRに関連した特定のマーカー (フォスフォ-STAT1 Y701,低フォスフォ-p27)
結論:
- 活性化されたIGF- 1R/ IRシグナリングは,HR+乳がんにおけるPGMに対するpCRの強化と関連しています.
- 免疫活性化マーカーはHR+とHR-サブグループの両方で応答を予測します.
- IGF- 1Rの活性化は,直接的に腫瘍の生物学と新補助療法に対する免疫反応に影響を与える可能性があります.
関連する概念動画
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
TGF - β Signaling Pathway
7.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K


